Andrew Mulato

3.1k total citations
33 papers, 2.1k citations indexed

About

Andrew Mulato is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Mulato has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 28 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Andrew Mulato's work include HIV Research and Treatment (28 papers), HIV/AIDS drug development and treatment (28 papers) and HIV/AIDS Research and Interventions (16 papers). Andrew Mulato is often cited by papers focused on HIV Research and Treatment (28 papers), HIV/AIDS drug development and treatment (28 papers) and HIV/AIDS Research and Interventions (16 papers). Andrew Mulato collaborates with scholars based in United States, France and Canada. Andrew Mulato's co-authors include Tomáš Cihlář, Julie M. Cherrington, Edmund Ho, Patrick D. Lamy, Gong-Xin He, S. Swaminathan, William A. Lee, Michael D. Fuller, Eugene Eisenberg and Kenneth C. Cundy and has published in prestigious journals such as Journal of Molecular Biology, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

Andrew Mulato

33 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Mulato United States	22	1.6k	1.2k	586	315	232	33	2.1k
Gabriel Birkuš United States	23	1.2k 0.8×	626 0.5×	577 1.0×	572 1.8×	194 0.8×	41	1.9k
Neil R. Hartman United States	19	1.1k 0.7×	917 0.8×	454 0.8×	503 1.6×	123 0.5×	41	1.9k
Brian L. Robbins United States	21	1.1k 0.7×	654 0.5×	397 0.7×	295 0.9×	101 0.4×	43	1.4k
Mauro Sciandra Italy	26	1.0k 0.6×	707 0.6×	488 0.8×	214 0.7×	303 1.3×	53	1.7k
Patricia Barditch‐Crovo United States	17	1.7k 1.1×	2.0k 1.7×	635 1.1×	320 1.0×	131 0.6×	27	3.0k
George J. Hanna United States	29	2.6k 1.7×	2.4k 2.0×	456 0.8×	231 0.7×	195 0.8×	77	3.1k
Takuma Shirasaka Japan	21	696 0.4×	539 0.5×	337 0.6×	210 0.7×	95 0.4×	87	1.4k
Joep MA Lange Netherlands	21	1.5k 1.0×	1.4k 1.2×	809 1.4×	120 0.4×	562 2.4×	42	2.4k
Marshall W. Fordyce United States	16	1.5k 0.9×	955 0.8×	443 0.8×	179 0.6×	233 1.0×	30	1.8k
Caroline E. Ridgway United Kingdom	12	948 0.6×	1.0k 0.8×	233 0.4×	180 0.6×	100 0.4×	12	1.4k

Countries citing papers authored by Andrew Mulato

Since Specialization

Citations

This map shows the geographic impact of Andrew Mulato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Mulato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Mulato more than expected).

Fields of papers citing papers by Andrew Mulato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Mulato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Mulato. The network helps show where Andrew Mulato may publish in the future.

Co-authorship network of co-authors of Andrew Mulato

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Mulato. A scholar is included among the top collaborators of Andrew Mulato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Mulato. Andrew Mulato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mulato, Andrew, Rima Acosta, Silvia Chang, et al.. (2020). Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 86(3). 369–377. 10 indexed citations

Mulato, Andrew, Rima Acosta, Stephen R. Yant, Tomáš Cihlář, & Kirsten White. (2020). 1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance. Open Forum Infectious Diseases. 7(Supplement_1). S726–S727. 2 indexed citations

Pohlmeyer, Christopher W., Veronica D. Gonzalez, Alivelu Irrinki, et al.. (2019). Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control. Journal of Virology. 93(7). 43 indexed citations

Mulato, Andrew, Derek Hansen, Danielle Porter, et al.. (2016). Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels. AIDS Research and Human Retroviruses. 32(12). 1237–1247. 5 indexed citations

Callebaut, Christian, Kirsten M. Stray, Luong Tsai, et al.. (2011). In VitroCharacterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with a Favorable Resistance Profile. Antimicrobial Agents and Chemotherapy. 55(4). 1366–1376. 29 indexed citations

Birkuš, Gabriel, Nilima Kutty, Gong-Xin He, et al.. (2008). Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases. Molecular Pharmacology. 74(1). 92–100. 82 indexed citations

Callebaut, Christian, Kirsten M. Stray, Leo L. Tsai, et al.. (2007). GS-8374, a Novel Phosphonate HIV Protease Inhibitor with Potent In Vitro Antiretroviral Activity, Low Metabolic Toxicity, and Favorable Resistance Profile. Antiviral Research. 74(3). A27–A27. 4 indexed citations

Cihlář, Tomáš, Gong-Xin He, Xiaohong Liu, et al.. (2006). Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated Solvent Anchoring. Journal of Molecular Biology. 363(3). 635–647. 47 indexed citations

Lee, William A., Gong-Xin He, Eugene Eisenberg, et al.. (2005). Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue. Antimicrobial Agents and Chemotherapy. 49(5). 1898–1906. 268 indexed citations

10.

Miller, Michael D., Nicolas Margot, Patrick D. Lamy, et al.. (2001). Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408. JAIDS Journal of Acquired Immune Deficiency Syndromes. 27(5). 450–458. 26 indexed citations

11.

Cihlář, Tomáš, et al.. (2001). HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS. Nucleosides Nucleotides & Nucleic Acids. 20(4-7). 641–648. 195 indexed citations

12.

Mulato, Andrew, Edmund Ho, & Tomáš Cihlář. (2000). Nonsteroidal Anti-Inflammatory Drugs Efficiently Reduce the Transport and Cytotoxicity of Adefovir Mediated by the Human Renal Organic Anion Transporter 1. Journal of Pharmacology and Experimental Therapeutics. 295(1). 10–15. 112 indexed citations

13.

Miller, Michael D., et al.. (1999). Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro. The Journal of Infectious Diseases. 179(1). 92–100. 117 indexed citations

14.

Wainberg, Mark A., Michael D. Miller, Yudong Quan, et al.. (1999). In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA. Antiviral Therapy. 4(2). 87–94. 205 indexed citations

15.

Cihlář, Tomáš, Michael D. Fuller, Andrew Mulato, & Julie M. Cherrington. (1998). A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selectedin Vitroby Cidofovir Confers a Slow Replication Phenotype in Cell Culture. Virology. 248(2). 382–393. 70 indexed citations

16.

Miller, Michael D., Patrick D. Lamy, Michael D. Fuller, et al.. (1998). Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity. Molecular Pharmacology. 54(2). 291–297. 22 indexed citations

17.

Xiong, Xiao‐Feng, Michael D. Fuller, Dirk B. Mendel, et al.. (1997). In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir). Antiviral Research. 36(2). 131–137. 11 indexed citations

18.

Mulato, Andrew & Julie M. Cherrington. (1997). Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Research. 36(2). 91–97. 56 indexed citations

19.

Deeks, Steven G., Ann C. Collier, Jacob Lalezari, et al.. (1997). The Safety and Efficacy of Adefovir Dipivoxil, a Novel Anti‐Human Immunodeficiency Virus (HIV) Therapy, in HIV‐Infected Adults: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 176(6). 1517–1523. 65 indexed citations

20.

Cherrington, Julie M., Michael D. Fuller, Andrew Mulato, et al.. (1996). Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrobial Agents and Chemotherapy. 40(5). 1270–1273. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact